A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients

Oncologist

Volumn 17, Issue 3, 2012, Pages 436-445

  Hottinger, Andreas F ^a   George, Anne Claude C ^a   Bel, Michael ^a   Favet, Laurence ^a   Combescure, Christophe ^a   Meier, Sara ^a   Grillet, Stéphane ^a   Posfay Barbe, Klara ^a   Kaiser, Laurent ^a   Siegrist, Claire Anne ^a   Dietrich, Pierre Yves ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; INFLUENZA VACCINE; PREDNISONE; RITUXIMAB; VIRUS ANTIBODY;

ADULT; AGE; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BREAST CANCER; CANCER PATIENT; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; FLU LIKE SYNDROME; GLIOMA; HEAD AND NECK CANCER; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE PAIN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; SINGLE DRUG DOSE; SWELLING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODY FORMATION; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEOPLASMS; OUTPATIENTS; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 84859401513     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0342     Document Type: Article

References (45)

1. Hajjar LA, Mauad T, Galas FR et al. Severe novel influenza A (H1N1) infection in cancer patients. Ann Oncol 2010;21:2333-2341.
2. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010;28:2481-2490.
3. Liu C, Schwartz BS, Vallabhaneni S et al. Pandemic (H1N1) 2009 infection in patients with hematologic malignancy. Emerg Infect Dis 2010;16: 1910-1917.
4. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 1997;102:2-9, discussion 25-26.
5. Feldman S, Webster RG, Sugg M. Influenza in children and young adults with cancer: 20 cases. Cancer 1977;39:350-353.
6. Ozdemir N, Celkan T, Midilli K et al. Novel influenza a (H1N1) infection in a pediatric hematology oncology clinic during the 2009-2010 pandemia. Pediatr Hematol Oncol 2011;28:288-293.
7. Meerveld-Eggink A, de Weerdt O, van der Velden AM et al. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol 2011;22:2031-2035.
8. Mazza JJ, Yale SH, Arrowood JR et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005;3:214-220.
9. Matsuzaki A, Suminoe A, Koga Y et al. Immune response after influenza vaccination in children with cancer. Pediatr Blood Cancer 2005;45:831-837.
10. Stiver HG, Weinerman BH. Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. Can Med Assoc J 1978; 119:733-735, 738.
11. Feery BJ, Sullivan JR, Hurley TH et al. Immunization with influenza vaccine in patients with haematological malignant disease. Med J Aust 1977; 1:292-294.
12. Gribabis DA, Panayiotidis P, Boussiotis VA et al. Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol 1994;91: 115-118.
13. Nordy T, Aaberge IS, Husebekk A et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002;19:71-78.
14. Centkowski P, Brydak L, Machala M et al. Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. J Clin Immunol 2007; 27:339-346.
15. Shildt RA, Luedke DW, Kasai G et al. Antibody response to influenza immunization in adult patients with malignant disease. Cancer 1979;44: 1629-1635.
16. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: A review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009;9:493-504.
17. European Medicines Agency. Pandemic Influenza (H1N1). Summary of Product Characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/02/, accessed September, 2011.
18. Clark TW, Pareek M, Hoschler K et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009;361:2424-2435.
19. Schwarz TF, Horacek T, Knuf M et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009;27:6284-6290.
20. Gabay C, Bel M, Combescure C et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011;63:1486-1496.
21. Ikram H, Prince AM. A method for coupling cytomegalovirus antigens to aldehyde-fixed erythrocytes for use in passive hemagglutination. J Virol Methods 1983;7:127-134.
22. Miller E, Hoschler K, Hardelid P et al. Incidence of 2009 pandemic influenza A H1N1 infection in England: A cross-sectional serological study. Lancet 2010;375:1100-1108.
23. Kempe A, Hall CB, MacDonald NE et al. Influenza in children with cancer. J Pediatr 1989;115: 33-39.
24. Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: Implications for prevention. Arch Intern Med 1982;142:85-89.
25. Elting LS, Whimbey E, Lo W et al. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 1995;3:198-202.
26. Rousseau B, Loulergue P, Mir O et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: The VACANCE study. Ann Oncol 2011;23:450-457.
27. Mohty B, Bel M, Vukicevic M et al. Graftversus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2011; 96:896-904.
28. Waddington C, Andrews N, Hoschler K et al. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsionadjuvanted (AS03(B)) split-virion versus nonadjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. Health Technol Assess 2010;14:1-130.
29. Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999; 17:99-104.
30. Jefferson TO, Rivetti D, Pietrantonj C et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007;(2):CD001269.
31. Ortqvist A, Berggren I, Insulander M et al. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin Infect Dis 2011;52:1203-1211.
32. Mackay HJ, McGee J, Villa D et al. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol 2011; 50:212-216.
33. Issa NC, Marty FM, Gagne LS et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011;17:434-438.
34. Anderson H, Petrie K, Berrisford C et al. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer 1999;80:219-220.
35. Brydak LB, Guzy J, Starzyk J et al. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 2001;9:65-68.
36. Ramanathan RK, Potter DM, Belani CP et al. Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients. J Clin Oncol 2002;20:4313-4318.
37. Ortbals DW, Liebhaber H, Presant CA et al. Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977;87:552-557.
38. Schafer AI, Churchill WH, Ames P et al. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer 1979;43:25-30.
39. Loulergue P, Alexandre J, Iurisci I et al. Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: Results of a prospective pilot study. Br J Cancer 2011;104:1670-1674.
40. Ademokun A, Wu YC, Dunn-Walters D. The ageing B cell population: Composition and function. Biogerontology 2010;11:125-137.
41. Bedognetti D, Zoppoli G, Massucco C et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximabcontaining regimens. J Immunol 2011;186:6044-6055.
42. Arad U, Tzadok S, Amir S et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011;29:1643-1648.
43. Andrews N, Waight P, Yung CF et al. Agespecific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011;203:32-39.
44. Fazekas de St Groth, Webster RG. Disquisitions of original antigenic sin. I. Evidence in man. J Exp Med 1966;124:331-345.
45. Kim JH, Skountzou I, Compans R et al. Original antigenic sin responses to influenza viruses. J Immunol 2009;183:3294-3301.